Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1996 Dec;149(6):1941–1952.

Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors.

E Brambilla 1, A Negoescu 1, S Gazzeri 1, S Lantuejoul 1, D Moro 1, C Brambilla 1, J L Coll 1
PMCID: PMC1865340  PMID: 8952529

Abstract

Neuroendocrine (NE) lung tumors comprise four classes of progressive aggressiveness for which proliferation and apoptosis rates could both contribute to their distinctive behavior. As p53 mutations may favor escape from apoptosis through changes in Bcl2-Bax expression balance, which are survival and apoptotic genes, respectively, we studied 121 NE lung tumors (16 typical carcinoids (TC), 5 atypical carcinoids (AC), 29 large-cell NE carcinomas (LCNECs), and 71 small-cell lung carcinomas (SCLCs) using immunohistochemistry. We quantified apoptosis by terminal-deoxynucleotidyl-transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) in 31 of these cases. There was a significant increase of p53 mutant immunophenotype (defined as immunoreactivity with at least two antibodies for at least 20% of tumor cells) between atypical/typical carcinoids group and the LCNEC/SCLC group (P = 0.0003). There was an inverse correlation (P < 0.0001) between the scores of Bax and Bcl2 expression in individual tumors and a significant inversion of the Bcl2. Bax ratio between low-grade (typical and atypical carcinoids) and high-grade (LCNECs and SCLCs) tumors with a predominant Bax expression in the first group and predominant Bcl2 expression in the second. Whereas carcinoids had variable apoptotic indexes, LCNECs had high indexes (1.3 to 6.8%), Bcl2 overexpression, Bax down-regulation, and Bcl2.Bax ratio > 1 correlated with lower apoptotic index in both LCNEC and the pool of LCNECs and SCLCs (P < 0.05) and a lower survival rate in the group of atypical and typical carcinoids and LCNECs (P < 0.002). The highest levels of Bcl2 expression and Bcl2.Bax ratios were associated with p53 mutant immunophenotype (P = 0.02). Our results suggest that aggressiveness in NE lung tumors could be linked, in addition to proliferation, to apoptosis-related factors.

Full text

PDF
1941

Images in this article

1944Figure 1
on p.1944

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aisenberg A. C., Wilkes B. M., Jacobson J. O. The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood. 1988 Apr;71(4):969–972. [PubMed] [Google Scholar]
  2. Arrigoni M. G., Woolner L. B., Bernatz P. E. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg. 1972 Sep;64(3):413–421. [PubMed] [Google Scholar]
  3. Ben-Ezra J. M., Kornstein M. J., Grimes M. M., Krystal G. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol. 1994 Nov;145(5):1036–1040. [PMC free article] [PubMed] [Google Scholar]
  4. Brambilla E., Gazzeri S., Moro D., Caron de Fromentel C., Gouyer V., Jacrot M., Brambilla C. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol. 1993 Jul;143(1):199–210. [PMC free article] [PubMed] [Google Scholar]
  5. Brambilla E., Moro D., Gazzeri S., Brichon P. Y., Nagy-Mignotte H., Morel F., Jacrot M., Brambilla C. Cytotoxic chemotherapy induces cell differentiation in small-cell lung carcinoma. J Clin Oncol. 1991 Jan;9(1):50–61. doi: 10.1200/JCO.1991.9.1.50. [DOI] [PubMed] [Google Scholar]
  6. Castle V. P., Heidelberger K. P., Bromberg J., Ou X., Dole M., Nuñez G. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol. 1993 Dec;143(6):1543–1550. [PMC free article] [PubMed] [Google Scholar]
  7. Chiou S. K., Rao L., White E. Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol. 1994 Apr;14(4):2556–2563. doi: 10.1128/mcb.14.4.2556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Colombel M., Symmans F., Gil S., O'Toole K. M., Chopin D., Benson M., Olsson C. A., Korsmeyer S., Buttyan R. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol. 1993 Aug;143(2):390–400. [PMC free article] [PubMed] [Google Scholar]
  9. D'Amico D., Carbone D., Mitsudomi T., Nau M., Fedorko J., Russell E., Johnson B., Buchhagen D., Bodner S., Phelps R. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene. 1992 Feb;7(2):339–346. [PubMed] [Google Scholar]
  10. Fontanini G., Vignati S., Bigini D., Mussi A., Lucchi M., Angeletti C. A., Basolo F., Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer. 1995 May;71(5):1003–1007. doi: 10.1038/bjc.1995.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gazzeri S., Brambilla E., Caron de Fromentel C., Gouyer V., Moro D., Perron P., Berger F., Brambilla C. p53 genetic abnormalities and myc activation in human lung carcinoma. Int J Cancer. 1994 Jul 1;58(1):24–32. doi: 10.1002/ijc.2910580106. [DOI] [PubMed] [Google Scholar]
  12. Gazzeri S., Brambilla E., Chauvin C., Jacrot M., Benabid A. L., Brambilla C. Analysis of the activation of the myc family oncogene and of its stability over time in xenografted human lung carcinomas. Cancer Res. 1990 Mar 1;50(5):1566–1570. [PubMed] [Google Scholar]
  13. Gazzeri S., Brambilla E., Jacrot M., Chauvin C., Benabid A. L., Brambilla C. Activation of myc gene family in human lung carcinomas and during heterotransplantation into nude mice. Cancer Res. 1991 May 15;51(10):2566–2571. [PubMed] [Google Scholar]
  14. Gouyer V., Gazzeri S., Brambilla E., Bolon I., Moro D., Perron P., Benabid A. L., Brambilla C. Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuro-endocrine lung carcinomas. Int J Cancer. 1994 Sep 15;58(6):818–824. doi: 10.1002/ijc.2910580612. [DOI] [PubMed] [Google Scholar]
  15. Harbour J. W., Lai S. L., Whang-Peng J., Gazdar A. F., Minna J. D., Kaye F. J. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 1988 Jul 15;241(4863):353–357. doi: 10.1126/science.2838909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Higashiyama M., Doi O., Kodama K., Yokouchi H., Tateishi R. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Anticancer Res. 1995 Mar-Apr;15(2):503–505. [PubMed] [Google Scholar]
  17. Jiang S. X., Sato Y., Kuwao S., Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol. 1995 Oct;177(2):135–138. doi: 10.1002/path.1711770206. [DOI] [PubMed] [Google Scholar]
  18. Johnson B. E., Makuch R. W., Simmons A. D., Gazdar A. F., Burch D., Cashell A. W. myc family DNA amplification in small cell lung cancer patients' tumors and corresponding cell lines. Cancer Res. 1988 Sep 15;48(18):5163–5166. [PubMed] [Google Scholar]
  19. Kerr J. F., Wyllie A. H., Currie A. R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972 Aug;26(4):239–257. doi: 10.1038/bjc.1972.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Krajewski S., Chatten J., Hanada M., Reed J. C. Immunohistochemical analysis of the Bcl-2 oncoprotein in human neuroblastomas. Comparisons with tumor cell differentiation and N-Myc protein. Lab Invest. 1995 Jan;72(1):42–54. [PubMed] [Google Scholar]
  21. Krajewski S., Krajewska M., Shabaik A., Miyashita T., Wang H. G., Reed J. C. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol. 1994 Dec;145(6):1323–1336. [PMC free article] [PubMed] [Google Scholar]
  22. Lithgow T., van Driel R., Bertram J. F., Strasser A. The protein product of the oncogene bcl-2 is a component of the nuclear envelope, the endoplasmic reticulum, and the outer mitochondrial membrane. Cell Growth Differ. 1994 Apr;5(4):411–417. [PubMed] [Google Scholar]
  23. Lohmann D. R., Fesseler B., Pütz B., Reich U., Böhm J., Präuer H., Wünsch P. H., Höfler H. Infrequent mutations of the p53 gene in pulmonary carcinoid tumors. Cancer Res. 1993 Dec 1;53(23):5797–5801. [PubMed] [Google Scholar]
  24. Marchetti A., Buttitta F., Merlo G., Diella F., Pellegrini S., Pepe S., Macchiarini P., Chella A., Angeletti C. A., Callahan R. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res. 1993 Jun 15;53(12):2846–2851. [PubMed] [Google Scholar]
  25. Miyashita T., Harigai M., Hanada M., Reed J. C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994 Jun 15;54(12):3131–3135. [PubMed] [Google Scholar]
  26. Miyashita T., Krajewski S., Krajewska M., Wang H. G., Lin H. K., Liebermann D. A., Hoffman B., Reed J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994 Jun;9(6):1799–1805. [PubMed] [Google Scholar]
  27. Miyashita T., Reed J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995 Jan 27;80(2):293–299. doi: 10.1016/0092-8674(95)90412-3. [DOI] [PubMed] [Google Scholar]
  28. Oltvai Z. N., Milliman C. L., Korsmeyer S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993 Aug 27;74(4):609–619. doi: 10.1016/0092-8674(93)90509-o. [DOI] [PubMed] [Google Scholar]
  29. Peled A., Zipori D., Rotter V. Cooperation between p53-dependent and p53-independent apoptotic pathways in myeloid cells. Cancer Res. 1996 May 1;56(9):2148–2156. [PubMed] [Google Scholar]
  30. Pezzella F., Turley H., Kuzu I., Tungekar M. F., Dunnill M. S., Pierce C. B., Harris A., Gatter K. C., Mason D. Y. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med. 1993 Sep 2;329(10):690–694. doi: 10.1056/NEJM199309023291003. [DOI] [PubMed] [Google Scholar]
  31. Pilotti S., Collini P., Rilke F., Cattoretti G., Del Bo R., Pierotti M. A. Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol. 1994 Apr;172(4):337–342. doi: 10.1002/path.1711720408. [DOI] [PubMed] [Google Scholar]
  32. Raff M. C. Social controls on cell survival and cell death. Nature. 1992 Apr 2;356(6368):397–400. doi: 10.1038/356397a0. [DOI] [PubMed] [Google Scholar]
  33. Sameshima Y., Matsuno Y., Hirohashi S., Shimosato Y., Mizoguchi H., Sugimura T., Terada M., Yokota J. Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene. 1992 Mar;7(3):451–457. [PubMed] [Google Scholar]
  34. Sato T., Hanada M., Bodrug S., Irie S., Iwama N., Boise L. H., Thompson C. B., Golemis E., Fong L., Wang H. G. Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9238–9242. doi: 10.1073/pnas.91.20.9238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Silvestrini R., Veneroni S., Daidone M. G., Benini E., Boracchi P., Mezzetti M., Di Fronzo G., Rilke F., Veronesi U. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1994 Apr 6;86(7):499–504. doi: 10.1093/jnci/86.7.499. [DOI] [PubMed] [Google Scholar]
  36. Takahashi T., Obata Y., Sekido Y., Hida T., Ueda R., Watanabe H., Ariyoshi Y., Sugiura T., Takahashi T. Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. Cancer Res. 1989 May 15;49(10):2683–2688. [PubMed] [Google Scholar]
  37. Takahashi T., Takahashi T., Suzuki H., Hida T., Sekido Y., Ariyoshi Y., Ueda R. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene. 1991 Oct;6(10):1775–1778. [PubMed] [Google Scholar]
  38. Travis W. D., Linnoila R. I., Tsokos M. G., Hitchcock C. L., Cutler G. B., Jr, Nieman L., Chrousos G., Pass H., Doppman J. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991 Jun;15(6):529–553. doi: 10.1097/00000478-199106000-00003. [DOI] [PubMed] [Google Scholar]
  39. al-Saffar N., Moore J. V., Hasleton P. S. A morphometric analysis of individual cell death in bronchial carcinoids. Cell Tissue Kinet. 1990 Jul;23(4):325–330. doi: 10.1111/j.1365-2184.1990.tb01128.x. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES